Navigation Links
Watson Confirms NIASPAN(R) Patent Challenge
Date:3/19/2012

orward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the difficulty of predicting the timing or outcome of product development efforts, including FDA and other regulatory agency approvals and actions, if any; the difficulty of predicting the timing and outcome of the pending patent litigation; the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's annual report on Form 10-K for the year ended December 31, 2011. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

NIASPAN® is a registered trademark of Abbott Respiratory LLC.

CONTACTS:

Investors:

Patty Eisenhaur
(862) 261-8141

Media:
Charlie Mayr
(862) 261-8030

(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO )


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... /PRNewswire-iReach/ -- CountryFocus: Healthcare, Regulatory and Reimbursement Landscape ... (Photo - http://photos.prnewswire.com/prnh/20140828/140879 ) ... Landscape Poland " an essential source of information ... market and provides insights into the demographic, regulatory, ... report provides valuable insights into the trends and ...
(Date:8/28/2014)... Aug. 28, 2014 Tianyin Pharmaceutical Co., ... pharmaceutical company that specializes in patented biopharmaceutical, modernized ... pharmaceutical ingredients (API) today updates the timeline for ... (QLF). The Company is scheduled ... for China Food & Drug Administration,s (CFDA) review ...
(Date:8/28/2014)... 2014 /PRNewswire-iReach/ -- Academy Leadership, an elite leadership training ... published a case study highlighting one manager,s ... . In September and October 2014, Academy Leadership affiliates ... Albuquerque , Indianapolis , Salt Lake City ... http://photos.prnewswire.com/prnh/20140828/140814 Leadership training for ...
Breaking Medicine Technology:Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 2Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 3Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 4Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 5TPI Submits Dataset for GMP Inspection at Qionglai Facility (QLF) 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 3Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 4Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 5
... During Wednesday,s Satellite Symposium,3: The Challenges of ... the,International Society of Heart and Lung Transplantation ... researchers discussed some of,the unique challenges in ... CF., A highlight of the session ...
... to be Presented at the Upcoming ECCMID Conference, ... the,press release published on 9 April, Arpida Ltd. ... the clinical programme with,intravenous iclaprim in complicated Skin ... has been presented at last year,s ICAAC,and IDSA ...
Cached Medicine Technology:Lung Transplants in Cystic Fibrosis Patients With Life-Threatening Bacteria Sparks Debate at ISHLT Meeting 2Lung Transplants in Cystic Fibrosis Patients With Life-Threatening Bacteria Sparks Debate at ISHLT Meeting 3Arpida Provides Further Comments on the Pivotal Phase III Trials 2Arpida Provides Further Comments on the Pivotal Phase III Trials 3Arpida Provides Further Comments on the Pivotal Phase III Trials 4
(Date:8/28/2014)... (PRWEB) August 28, 2014 American adults ... industry on the Internet will now have a simpler ... company. In one click this year, some of the ... http://quotespros.com/life-insurance.html . , The promoted plans that ... Pros finder tool represent popular policies. The term, guaranteed ...
(Date:8/28/2014)... NH As the federal government plans its exit strategy ... to rethink its role in providing health care to veterans, ... of Medicine . , "To simply go on doing more ... that the Veterans Health Administration,s cost and population structure pose ... Institute for Health Policy & Clinical Practice, and David Auerbach, ...
(Date:8/28/2014)... and Ann Arbor, MI (PRWEB) August 28, 2014 ... company and the nation’s leading intraoperative neurophysiology monitoring ("IONM") ... and CFO, to the position of Chief Executive Officer ... CFO, was promoted to President and CFO in 2013 ... growth and success. , “Bill’s efforts and achievements ...
(Date:8/28/2014)... Kirklyn Smith, an office manager for EzCOI.com , ... record by walking 5,000 miles in a single year without ... the thousands of individual stories of TrekDesk treadmill desk users ... more than the others. , Kirklyn has launched a website ... a range of 54,823 steps (presumably on an off day) ...
(Date:8/28/2014)... San Mateo, CA (PRWEB) August 28, 2014 ... announce that the MRI Technology program is re-accredited for ... Registry of Magnetic Resonance Imaging Technologists (ARMRIT). , ... re-accreditation. We are constantly improving our program to make ... There is a lot of interest in MRI field ...
Breaking Medicine News(10 mins):Health News:Best Life Insurance Rates for 2014 Now Promoted at Insurer Website 2Health News:A VA exit strategy 2Health News:Biotronic NeuroNetwork Announces the Promotion of Bill Gecsey to CEO 2Health News:There are many reasons why Americans' exercise levels have declined - Meet an executive that refuses to sit still with his TrekDesk Treadmill Desk even in a sedentary job 2Health News:Gurnick Academy’s MRI Program Is Re-Accredited by ARMRIT for the 5 Years 2
... 2008 Barr,Pharmaceuticals, Inc. (NYSE: BRL ) today ... 8:30AM Eastern time on Thursday, May 8 to discuss,earnings ... March 31,2008. The number to call from within the ... replay of the conference call will be,available from 10:30AM ...
... 7, 2008 Edmond Medical Center and,ophthalmologists M. Andrew ... Eye Associates, will once again participate in the Mission,Cataract ... those who cannot afford to pay., Appointments can ... If the patient qualifies for the cataract surgery and ...
... to increased risk of falls in the elderly can ... the Electronic Health Record, new Geisinger research shows. ... a persons neurochemistry and may predispose elderly patients to ... death in the elderly. , Geisinger pharmacists and geriatricians ...
... Foster Career School,now offers allied health certificate programs ... offerings include a variety of,online certificate programs such ... broad overview of the human body is ideal ... medical transcriptionists, and,first aid technicians can learn the ...
... Stiefel Laboratories,Inc., the world,s largest independent pharmaceutical company ... has been,promoted to the newly created position of ... chief scientific officer will reinforce the,already critical role ... between,all R&D departments. It also will further strengthen ...
... may not only play a central role in the ... also in much more common acquired chronic lung diseases ... chronic obstructive pulmonary disease (COPD). This is the conclusion ... direction of Assistant Professor Dr. Marcus Mall from the ...
Cached Medicine News:Health News:Barr Will Host An Earnings Conference Call on May 8, 2008 to Discuss the Results for the First Quarter of Calendar 2008 2Health News:Barr Will Host An Earnings Conference Call on May 8, 2008 to Discuss the Results for the First Quarter of Calendar 2008 3Health News:Edmond Medical Center to Provide Free Cataract Surgeries 2Health News:Penn Foster Career School Offers Certificate Programs 2Health News:Stiefel Laboratories Appoints First Chief Scientific Officer 2Health News:Stiefel Laboratories Appoints First Chief Scientific Officer 3Health News:Asthma and smoker's lung: dry airways play a key role 2Health News:Asthma and smoker's lung: dry airways play a key role 3
Kit Nebulizer Small Volume Medication W/Pediatric Mask Mouthpiece 7FT O 2 Tubing...
Nebulizer Adapter Kit 6"...
... Anesthesia and Respiratory Products, ,Westmed designs, ... for Anesthesia and Respiratory professionals. Our mission ... enhance the clinician's ability to deliver quality ... the bottom line. , ,Our web ...
... The Raindrop® medication nebulizer achieves optimum ... MMAD particle size range is 1.04-1.10 µ ... compressor or air outlet., ,As the ... gives healthcare providers the assurance of proven ...
Medicine Products: